奈达铂治疗晚期非小细胞肺癌临床疗效的观察  

Clinical trial/study of nedaplatin in advanced non-small cell lung cancer

作　　者：蔡君[1] 胡艳[1] 李晶晶[1] 周琼[1] 付国权[1] 李爽[1] 蒋代文[1] 杨继元[1] 

机构地区：[1]长江大学第一附属医院肿瘤科,湖北荆州434000

出　　处：《中华肿瘤防治杂志》2011年第20期1632-1634,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:观察含奈达铂(NDP)化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:96例ⅢB或者Ⅳ期NSCLC患者,随机分为NDP组和顺铂(DDP)组,A组:NDP 80～100mg/m2,静脉滴入,d1。B组:DDP 80～100mg/m2,静脉滴入,d1或分3d,两组均分别联合长春瑞滨、泽菲或者多西紫杉醇化疗。21d为1个周期,治疗4～6个周期。结果:A组总有效率为38.0%,鳞癌有效率为51.9%,腺癌有效率为21.7%,两者疗效比较差异有统计学意义,χ2=4.78,P<0.05。B组总的有效率为41.3%,鳞癌化疗有效率为40.9%,腺癌化疗有效率为41.7%,两者疗效比较差异无统计学意义,χ2=0.003,P>0.05。A组的胃肠道反应较B组明显减轻。骨髓抑制和肝肾功能损坏大致相同。A组中位疾病进展时间6.8个月,B组中位疾病进展时间6.7个月,两组比较差异无统计学意义,P>0.05。A组中位生存时间11.9个月,B组中位生存时间12.5个月,两组中位生存时间差异无统计学意义,P>0.05。A组1和2年生存率分别为45.0%和2.0%,而B组1和2年生存率分别42.0%和3.2%,均差异无统计学意义,P>0.05。结论:含NDP的化疗方案治疗晚期NSCLC疗效与DDP组相当,但毒副反应较轻,尤其适用于转移性鳞癌。OBJECTIVE： To observe the efficacy and the adverse reaction of nedaplatin in treatment of non-small cell lung cancer （NSCLC）. METHODS：Totally 96 patients with stage III B or IV NSCLC were enrolled and divided randomly into two groups. Group A： Nedaplatin（80 - 100 mg/m2 , d1 ） combined with Navelbine or Docetaxel or Gemcitabine. Group B： Cisplatin 80--100 mg/m2 also combined with Navelbine or Docetaxel or Gemcitabine, repeated every 3 weeks. The efficancy of the two groups were evaluated after 4 to 6 cycles. RESULT： The overall response rate was 38. 0% in group A. There was a significant difference（x2= 4.78, P〈0.05） between squamous cell carcinoma （OR= 51.9% ） and adenocarcino- ma（OR=21.7%）. The overall response rate was 41.3% in group B. There was no significant difference （X2 = 0. 003, P 〉 0.05） between squamous cell carcinoma （OR= 40.9%） and adenocarcinoma （OR ： 41. 7%）. The gastrointestinal symptom of group A was slighter. The bone marrow, hematological and renal toxicity were similar in both groups. The median time to progression was 6. 8 months in group A and 6. 7 months in group B, which showed no significant difference （P〉 0.05）. The median survival time was 11.9 months in the group A and 12. 5 months in group B, which was no significant difference （P 〉 0.05）. The survival rates of 1 year and 2 year in group A were 45.0% and 2.0% respectively, while rates in group B were 42.0% and 3. 2% respectively, and none of the difference was significant statistical （P〉0.05）. CONCLUSION： The chemotherapy combined with nedaplatin are as effective as combined with DDP in advanced NSCLC, but appear less adverse events and recommended especially to deal with squamous cell carcinoma.

关 键 词：癌 非小细胞肺/药物疗法 抗肿瘤联合化疗方案 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]